The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Eli Lilly's oral GLP-1 medication Foundayo launched to quieter-than-expected demand, raising questions for patients weighing oral versus injectable options. Here's what the slow start actually means for your treatment choices, costs, and access in 2025 and beyond. We break it down without the hype.
High fashion is pushing back against the slimmer silhouettes associated with GLP-1 medications like Ozempic and Wegovy. This cultural moment raises real questions for people on these medications about body image, stigma, and staying grounded in their health goals. Here's how to tune out the noise and focus on what actually matters.
Research is finding a surprising connection between GLP-1 medications like Ozempic and Wegovy and reduced use of alcohol, tobacco, and other risky substances. The same brain pathways that drive overeating may also drive addictive behaviors, and GLP-1 drugs appear to influence both. Here's what patients should know.
Bank of America is warning that patient dropout from Wegovy could put pressure on Hims & Hers financials. For people using or considering GLP-1 medications through telehealth platforms, this raises real questions about provider stability, medication access, and long-term costs. Here's what you need to know before choosing a platform.
Medicare coverage for Wegovy expanded to include patients with established heart disease, and prescriptions have surged as a result. If you're on Medicare and managing cardiovascular risk, this shift could significantly change what you pay and what you can access. Here's what you need to know.
The ease of buying GLP-1 medications online has raised serious safety concerns, including overdose risks, counterfeit drugs, and unregulated dosing. This guide helps you understand the dangers and how to find a legitimate provider who will actually protect your health.
Maryland is moving to cap the out-of-pocket cost of Ozempic and other GLP-1 medications, starting with state employees now and expanding to all residents by 2028. This policy shift could reshape how patients access and afford semaglutide across the state. Here's what you need to know and how to prepare.
CVS has reversed course and added Eli Lilly's obesity medication back to its formulary, potentially restoring coverage for millions of members. This shift has real implications for your out-of-pocket costs and access to tirzepatide. Here is what patients need to know right now.
